Submission guidelines for abstract submission to the Pharmaceutical 2025:
Submission Portal Submit your abstract through the designated online submission gate handed on the webinar website.
Abstract Format Prepare your abstract according to the specified format guidelines, including word count, fountain size, and formatting style.
Title give a terse and descriptive title that directly reflects the content of your exploration.
Authors List all authors' names, confederations, and contact information. Indicate the presenting author if different from the primary author.
Abstract Content easily state the objects, styles, results, and conclusions of your exploration within the abstract. Avoid bowdlerization’s and undetermined acronyms.
Keywords Include a list of applicable keywords or expressions to grease indexing and search ability.
Clarity and Conciseness Write your abstract in clear, terse language, avoiding gratuitous slang or specialized terms that may be unclear to compendiums.
Applicability insure that your abstract aligns with the webinar theme and focuses on motifs applicable to Pharmaceutical 2025.
Plates and Tables If applicable, include applicable plates, tables, or images to enhance understanding of your exploration findings. insure they're high quality and easily labelled.
References If citing former exploration or literature, include applicable references following the specified citation style.
Submission Deadline Submit your abstract by the specified deadline to be considered for donation at the webinar. Late cessions may not be accepted.
Evidence Upon successful submission, you should admit an evidence dispatch or announcement admitting your epitome.
Review Process objectifications will suffer a peer review process by the webinar scientific commission. announcement of acceptance or rejection will be communicated within the specified timeframe.
Donation Format If your epitome is accepted, follow the guidelines handed for oral or bill donation, including donation length, formatting conditions, and session scheduling.
NOTE: Download the abstract template from the below for submission reference.
Clinging to these submission guidelines will help insure that your epitome is duly formatted, applicable, and competitive for consideration at the Pharmaceutical 2025.
As drug companies fret over their finances, they are increasingly partnering with universities to help with early-stage research
2024-10-07 - 2024-12
Pharmaceutical companies are often lambasted for rising drug costs. For example, the price of new drugs entering the US market in 2023 was 35% higher than in 2022. According to an analysis from Reuters, part of the increase is due to a move to develop therapies for rare diseases: because fewer people have those condition, drug makers push up the per-dose price to recover their costs. But the cost of developing drugs for more common diseases, including cancers, is also rising rapidly.
AstraZeneca's £450 Million Vaccine Facility Faces Delays
2025-01-20 - 2025-01
AstraZeneca's planned £450 million investment in a new flu vaccine facility in Speke, Liverpool, has encountered setbacks due to delays in securing government support. Despite urgent warnings from the UK chairman to Business Secretary Jonathan Reynolds after Labour's election victory, early assurances regarding the government's advanced manufacturing plan were not provided promptly. Consequently, the project's timelines were affected, necessitating reworking to meet tight launch projections. The delays have led to frustration with the Whitehall process. The company had been seeking incentives and support to proceed with the investment. With AstraZeneca's significant contribution to the UK's life sciences sector and economy—being the largest private sector investor in UK R&D and employing around 8,700 people—the delays have put pressure on the government to secure private sector investment for economic growth. The government asserts its commitment to supporting innovative medicine development and is in active discussions with AstraZeneca.
AI and Large Language Models Transforming Pharma
2025-01-05 - 2025-01
A recent study highlights the transformative potential of artificial intelligence (AI) and large language models (LLMs) in the pharmaceutical industry. AI applications span various operational areas, including research and development, clinical trials, production, regulatory affairs, and quality control. Machine learning algorithms, in particular, are contributing to advancements in drug discovery and development, offering promising avenues for innovation and efficiency.
